Vitamin D for Cognition in Bipolar Disorder

Taipei City Hospital21 enrolled

Overview

Conduct randomized double-blind controlled trial (RCT), to examine the effects of vitamin D on cognitive performance in euthymic BD.

Bipolar disorder (BD) is a chronic mental disease related to recurrent episodes along with cognitive or functional decline. Comparing efficacy of pharmacological interventions targeting to treat cognitive deficit in BD is unexplored. The majority of the observational studies demonstrate a significant association between low serum vitamin D and compromised cognition in a wide range of neuropsychiatry diseases. Recent survey further revealed the high prevalence of hypovitamin D in BD. The effect of supplement and association between vitamin D and cognition in BD and the underlying mechanism is unclear. The investigators will collect vitamin D levels and assess their association with cognition in a euthymic bipolar cohort (N=200) for screen. Then, the investigators estimate to recruit 120 of participants with cognitive deficits and combined vitamin D deficiency, to conduct a RCT. Participants will keep their usual treatment and will be randomized to receive either vitamin D supplement or a placebo for eight weeks. Cognitive test, adverse side effect, mood status and blood 25(OH)D levels and biomarkers will be measured before and after intervention.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Bipolar Disorder

Interventions

solubilized vitamin D3DIETARY_SUPPLEMENT

solubilized vitamin D3

medium chain triglycerideDIETARY_SUPPLEMENT

MCT with same amount

Eligibility

Sex: ALLMin age: 20 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients who diagnosed with BD-I based on the Diagnostic and Statistical Manual (DSM-IV) criteria are consecutively referred by board-certified psychiatrists in Taipei City Hospital, Songde branch. 2. Age of participants should range from 20 to 65 years old. 3. No history of vitamin D supplementation within three months before the study. 4. The BD patients in their euthymic state (both Hamilton Depression Rating Scale and Young Mania Rating Scale ≤ 8) and no change of their psychoactive medications in recent three months. Exclusion Criteria: 1. With known substance use disorder (except nicotine use disorder) 2. With any disorder with known neurological symptoms or complications (ex. brain injury, stroke or brain lesions) 3. Comorbid with schizophrenia spectrum disorders 4. With active physical condition (such as renal impairment, hepatic failure…) or pregnancy 5. Inability to complete the standard assessment or incapability of providing informed consent

Locations (1)

Taipei City hospital

Taipei, Taiwan

Outcomes

Primary Outcomes

change of cognition

Change from Baseline Brief Assessment of Cognition in Affective Disorders (BAC-A) score at week 10

Time frame: Week 0, Week 10

Secondary Outcomes

change of serum vitamin D levels

change from baseline serum vitamin D levels to week 10, unit: ng/mL

Time frame: Week 0, Week 10

change of serum creatinine

change from baseline serum creatinine to week 10, unit: mg/dL

Time frame: Week 0, Week 10

change of blood albumin

change from baseline blood albumin to week 10, unit: g/dL

Time frame: Week 0, Week 10

change of blood parathyroid hormone

change from baseline parathyroid hormone to week 10, unit: pg/mL

Time frame: Week 0, Week 10

change of serum calcium levels

change from baseline serum calcium levels to week 10, unit: mg/dL

Time frame: Week 0, Week 10

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.